Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AT-527 PK in Renal Impairment and Probenecid Interaction
NCT05618314Phase 1Completed
- Sponsor
- Atea Pharmaceuticals
- Start
- Oct 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of bemnifosbuvir in hepatitis C (HCV) and coronavirus disease 2019 (COVID-19) (5 arms), sponsored by Atea Pharmaceuticals. Primary endpoints: Maximum plasma concentration of AT-527 at Day 1 and Area under the plasma concentration-time curve of AT-527 at Day 1. Started Oct 2022; status: completed.
02
Drugs
bemnifosbuvir
03
Conditions
hepatitis C (HCV)coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05618314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05618314.